Key Research Statistics
Enhanced Growth Factor
100xReduced IGFBP BindingR3 substitution + N-terminal extension → longer free circulation
>50%Body Weight Gain ReductionAnimal model: 15.8 g vs 35.6 g controls — preclinical.
Potency vs Native IGF-1
Molecular engineering advantages
IGF-1 LR3 Anabolic2.5x
Native IGF-11x
Receptor binding studies
Half-Life Comparison
Extended bioactivity window
IGF-1 LR325hrs
Native IGF-113hrs
Pharmacokinetic data (animal)
Research consideration — malignancy historyIGF-1 LR3 is a potent growth signal. Elevated IGF-1 activity has been linked to accelerated growth of pre-existing malignancies (notably breast, prostate, and colorectal). Not suitable for research in subjects with a personal or family history of cancer.
IGF-1 LR3 at the Cellular Level
Insulin-like growth factor

IGF-1 LR3 in the Body
Extended-half-life insulin-like growth factor

Complete Your Protocol
Complementary compounds from other research areas






